* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 14 cents per share for the quarter ended in March,
identical to the same quarter last year. The mean expectation
of nine analysts for the quarter was for a loss of 17 cents per
share. Wall Street expected results to range from -25 cents
to -13 cents per share.
* Revenue fell 18.4% to $9.95 million from a year ago;
analysts
expected $10.84 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 14 cents.
* The company reported a quarterly loss of $40.61 million.
* Abcellera Biologics Inc shares had fallen by 10.8% this
quarter and lost 29.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 33%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Abcellera
Biologics Inc is $14.50
This summary was machine generated from LSEG data May 8 at 07:40
a.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.17 -0.14 Beat
Dec. 31 2023 -0.13 -0.17 Missed
Sep. 30 2023 -0.13 -0.10 Beat
Jun. 30 2023 -0.13 -0.11 Beat